Y Intercept Hong Kong Ltd Invests $704,000 in ANI Pharmaceuticals, Inc. $ANIP

Y Intercept Hong Kong Ltd purchased a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 3rd quarter, HoldingsChannel.com reports. The firm purchased 7,690 shares of the specialty pharmaceutical company’s stock, valued at approximately $704,000.

A number of other large investors have also added to or reduced their stakes in the stock. Rubric Capital Management LP boosted its stake in ANI Pharmaceuticals by 354.7% in the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after acquiring an additional 200,998 shares during the last quarter. Teacher Retirement System of Texas raised its holdings in shares of ANI Pharmaceuticals by 3,156.3% in the 2nd quarter. Teacher Retirement System of Texas now owns 147,380 shares of the specialty pharmaceutical company’s stock worth $9,617,000 after purchasing an additional 142,854 shares during the period. Global Alpha Capital Management Ltd. lifted its stake in ANI Pharmaceuticals by 17.2% in the second quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock valued at $56,251,000 after purchasing an additional 126,500 shares during the last quarter. First Trust Advisors LP grew its holdings in ANI Pharmaceuticals by 128.1% during the second quarter. First Trust Advisors LP now owns 81,214 shares of the specialty pharmaceutical company’s stock valued at $5,299,000 after purchasing an additional 45,613 shares during the period. Finally, PDT Partners LLC purchased a new stake in ANI Pharmaceuticals in the second quarter worth $2,965,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Transactions at ANI Pharmaceuticals

In related news, Director Patrick D. Walsh sold 8,643 shares of the stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $86.88, for a total value of $750,903.84. Following the sale, the director owned 61,405 shares in the company, valued at approximately $5,334,866.40. This trade represents a 12.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Renee P. Tannenbaum sold 1,800 shares of ANI Pharmaceuticals stock in a transaction on Friday, December 5th. The shares were sold at an average price of $81.15, for a total value of $146,070.00. Following the sale, the director directly owned 25,157 shares of the company’s stock, valued at $2,041,490.55. This represents a 6.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 28,101 shares of company stock worth $2,453,063. 12.70% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Trading Down 2.3%

Shares of ANIP opened at $80.00 on Tuesday. The business’s 50-day moving average price is $81.88 and its 200-day moving average price is $85.30. ANI Pharmaceuticals, Inc. has a twelve month low of $54.10 and a twelve month high of $99.50. The stock has a market cap of $1.80 billion, a PE ratio of 49.08 and a beta of 0.50. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. The company had revenue of $227.81 million during the quarter, compared to analyst estimates of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. ANI Pharmaceuticals’s revenue was up 53.6% compared to the same quarter last year. During the same period last year, the business earned $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ANIP shares. Barclays began coverage on ANI Pharmaceuticals in a research report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research note on Thursday, October 9th. Guggenheim boosted their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Finally, Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $103.43.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.